Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Progressive Aphasia Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

NCT06511752
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia, Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease
Interventions
Psychosocial educational, support group and implementation of strategies
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1

NCT03887533
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
VTS-270
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Tau PET Imaging in Atypical Dementias

NCT03283449
View directory record Official record
Conditions
Primary Progressive Aphasia With Suspected Alzheimer's Disease
Interventions
18F-AV-1451, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

NCT00703677
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Lithium
Drug
Lead sponsor
Westat
Other
Eligibility
40 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT03088956
View directory record Official record
Conditions
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Interventions
Assessments
Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 19, 2026, 8:02 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Learning Amyloid and Tau Results

NCT07222930
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Disclose amyloid, tau results, Follow-up Assessments
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
45 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)

NCT05615922
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity
Device · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
45 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational

4 Repeat Tauopathy Neuroimaging Initiative

NCT01804452
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C

NCT03471143
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
VTS-270
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 6 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Lithium As a Treatment to Prevent Impairment of Cognition in Elders

NCT03185208
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Lithium Carbonate, Placebo oral capsule
Drug
Lead sponsor
Ariel Gildengers, MD
Other
Eligibility
60 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting No phase listed Observational

Clinical Procedures to Support Research in ALS

NCT03489278
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
11
States / cities
Irvine, California • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 3

NCT02854033
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Enrolling by invitation Not applicable Interventional

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

NCT07222605
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration, Posterior Cortical Atrophy (PCA), Neurological Diseases or Conditions, Dementia
Interventions
MemorEM
Device
Lead sponsor
eQ8Health Corporation d/b/a CareONE Concierge
Industry
Eligibility
45 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT04958642
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

NCT03636204
View directory record Official record
Conditions
Healthy, Frontotemporal Dementia
Interventions
AL001, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 19, 2026, 8:02 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481
View directory record Official record
Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

NCT03759639
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

NCT02612129
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
arimoclomol, Placebo
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
2 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Oakland, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT05741853
View directory record Official record
Conditions
Primary Progressive Aphasia, Dementia, Dementia, Frontotemporal, Alzheimer Disease, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, Apraxia, Motor, Dysarthria, Communication Disorders, Language Disorders, Speech Disorders, Neurocognitive Disorders, Aphasia, Bilingual Aphasia
Interventions
Video-Implemented Script Training for Aphasia (VISTA), Lexical Retrieval Training (LRT)
Behavioral
Lead sponsor
Stephanie Grasso
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Caregiver Online Survey (Dementia and Swallowing Difficulties)

NCT06471660
View directory record Official record
Conditions
Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia, Mild, Dementia Moderate, Dementia Severe, Parkinson Disease Dementia, Dementia Frontotemporal
Interventions
Not listed
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

NCT02292654
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 19, 2026, 8:02 AM EDT